Skip to main content
SpringerLink
Log in

Clinical Trials Update Esc Congress 2011

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

    Article  PubMed  CAS  Google Scholar 

  2. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975–83.

    Article  PubMed  CAS  Google Scholar 

  3. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

    Article  PubMed  CAS  Google Scholar 

  4. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699–708.

    Article  PubMed  CAS  Google Scholar 

  5. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.

    Article  PubMed  CAS  Google Scholar 

  6. Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387–94.

    Article  PubMed  CAS  Google Scholar 

  7. Cohen M. Oral antiplatelet therapy for acute and chronic management of NSTE ACS: Residual ischemic risk and opportunities for improvement. Cardiovasc Drugs Ther. 2009;23:489–99.

    Article  PubMed  CAS  Google Scholar 

  8. Hanna EB, Glancy DL, Saucedo JF. Antiplatelet and anticoagulant therapies in acute coronary syndromes. Cardiovasc Drugs Ther. 2010;24:61–70.

    Article  PubMed  CAS  Google Scholar 

  9. Oldgren J, Budaj A, Granger CB, For the RE-DEEM investigators, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32:2781–9.

    Article  PubMed  CAS  Google Scholar 

  10. Alexander JH, Becker RC, Bhatt DL, et al. on behalf of the APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119:2877/85

    Google Scholar 

  11. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind phase II trial. Lancet. 2009;374:29–38.

    Article  PubMed  CAS  Google Scholar 

  12. Heeringa M, Groenendaal D, Strabach G, et al. Co-administration of darexaban (YM150), an oral direct factor Xa inhibitor, with acetylsalicylic acid, clopidogrel and naproxen: no evidence of clinically relevant interactions. J Thromb Hemost. 2007;9:360.

    Google Scholar 

  13. Steg PG, Mehta SR, Jukema JW, et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. 2011;32:2541–54.

    Article  PubMed  CAS  Google Scholar 

  14. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre, randomized controlled trial. Lancet. 2003;361:1149–58.

    Article  PubMed  CAS  Google Scholar 

  15. Sever PS, Chang CL, Gupta A, Whitehouse A, Poulter NR, On the behalf of ASCOT investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J. 2011;32:2525–32.

    Article  PubMed  CAS  Google Scholar 

  16. Davidson M, Rosenson RS. HDL therapy: The next frontier. Am J Cardiol. 2009;104(10 Suppl):52E–7.

    Article  PubMed  CAS  Google Scholar 

  17. Barter PJ, Caulfield M, Eriksson M, ILLUMINATE Investigators, et al. Effects of torcetrapib in partients at high risk for coronary heart disease. N Engl J Med. 2007;357:2109–22.

    Article  PubMed  CAS  Google Scholar 

  18. Ranalletta M, Bierilo KK, Chen Y, et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res. 2010;51:2739–52.

    Article  PubMed  CAS  Google Scholar 

  19. Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010;51:3443–54.

    Article  PubMed  Google Scholar 

  20. Fayad ZA, Mani V, Woodward M, For the dal-PLAQUE Investigators, et al. Lancet 2011; Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomized clinical trial. Lancet. 2011;378:1547–59.

    Article  PubMed  CAS  Google Scholar 

  21. Rosenson RS. Functional assessment of HDL: Moving beyond static measures for risk assessment. Cardiovas Drugs Ther. 2010;24:71–5.

    Article  Google Scholar 

  22. Zannad F, McMurray JJV, Krum H, For the EMPHASIS-HF Study Group, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.

    Article  PubMed  CAS  Google Scholar 

  23. Pitt B, Zannad F, Remme WJ, For the Randomized Aldactone Evaluation Study (RALES) investigators, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.

    Article  PubMed  CAS  Google Scholar 

  24. Pitt B, Remme WJ, Zannad F, For the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.

    Article  PubMed  CAS  Google Scholar 

  25. Mulder P, Barbier S, Chagraoul A, et al. Log-term heart rate reduction induced by the selective I(f) inhibitor ivabradine improves left ventricular function and intrinsic myocardal structure in congestive heart failure. Circulation. 2004;109:1674–9.

    Article  PubMed  CAS  Google Scholar 

  26. Swedberg K, Komjda M, Ohm M, For the SHIFT investigators, et al. Ivabradine and outcomes in chronic heart failure (SHIFT); A randomised, placebo-controlled trial. Lancet. 2010;376:875–85.

    Article  PubMed  CAS  Google Scholar 

  27. Tardiff JC, O’Meara E, Komajda M, On behalf of the SHIFT Investigators, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32:2507–15.

    Article  Google Scholar 

  28. Ekman I, Chassany O, Komajda M, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: Results from the SHIFT study. Eur Heart J. 2011;32:2395–404.

    Article  PubMed  Google Scholar 

  29. Amosova E, Andrejev E, Zaderey I, Rudenko U, Ceconi C, Ferrari R. Efficacy of ivabradine in combination with beta-blocker versus uptitration of beta-blocker in patients with stable angina. Cardiovasc Drugs Ther. 2011;25:531–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mount Sinai School of Medicine, New York, USA

    Robert Rosenson

  2. University of Adelaide, South Australia, Australia

    John Horowitz

  3. University of London, London, UK

    Juan-Carlos Kaski

  4. Monash University, Melbourne, Australia

    Henry Krum

  5. Sticares Cardiovascular Research Institute, P.O.Box 882, 3160, AB, Rhoon, The Netherlands

    Willem Remme

Authors
  1. Robert Rosenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Horowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juan-Carlos Kaski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Henry Krum
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Willem Remme
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Willem Remme.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosenson, R., Horowitz, J., Kaski, JC. et al. Clinical Trials Update Esc Congress 2011. Cardiovasc Drugs Ther 26, 77–84 (2012). https://doi.org/10.1007/s10557-012-6371-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-012-6371-7

Key words

Search

Navigation